CN106806892A - A kind of gut flora regulating drug based on Yolk antibody - Google Patents
A kind of gut flora regulating drug based on Yolk antibody Download PDFInfo
- Publication number
- CN106806892A CN106806892A CN201510872579.5A CN201510872579A CN106806892A CN 106806892 A CN106806892 A CN 106806892A CN 201510872579 A CN201510872579 A CN 201510872579A CN 106806892 A CN106806892 A CN 106806892A
- Authority
- CN
- China
- Prior art keywords
- medicine according
- yolk antibody
- yolk
- antibody
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention provides a kind of gut flora regulating drug based on Yolk antibody, Yolk antibody, probiotics, interferon, azithromycin be used in combination the technical scheme novelty, the prevention or treatment to grice diarrhoea can be realized, formulation can select oral agents or injection.Medicine of the present invention by piglet applied IgG antibody can in immune response activating complement, various toxin are neutralized, so as to play prevention or therapeutic effect to the pathogenic microorganism for causing diarrhoea.And administration of probiotics can play intervention effect to gastrointestinal bacterial flora, promote the releveling of sick body gastrointestinal bacterial flora, so that auxiliary treatment.The present invention realizes prominent technique effect with the technology design of novelty, and its is evident in efficacy and easily prepared, therefore with prominent promotion prospect.
Description
Technical field
The present invention relates to veterinary biologicses technical field, and in particular to a kind of gut flora based on Yolk antibody
Regulating drug.
Background technology
Because piglet immunological systematic growth is not yet complete, the ability for resisting pathogenic microorganism is weaker, therefore easily occurs
Diarrhoea phenomenon.Produce diarrhoea the reason for be it is various, the difference according to its origin cause of formation can be divided into bacterial diarrhea,
Virus diarrhea, parasitic diarrhea and non-diseases diarrhoea.
Wherein the pathogenic microorganism of bacterial diarrhea include c-type clostridieum welchii, Escherichia coli, pig treponema,
Salmonella etc., can cause the illnesss such as piglet red dysentery, the white scour of piglet, piglet yellow scour, necrotic enteritis and then
Cause diarrhoea；The pathogenic microorganism of virus diarrhea mainly includes Porcine epidemic diarrhea virus (PEDV), pig
TGE (TGEV), rotavirus (PVV) etc.；Parasitic diarrhea more by coccidia,
Roundworm, trypanosome cause, and the course of disease is more long；Rather than disease diarrhoea is mainly caused by trophic factor, such as short time
Too high, hypovitaminosis of protein content etc. is taken in, environmental stress factor is likely to cause piglet to produce diarrhoea in addition
Symptom.The harmfulness maximum of the factor that the above causes grice diarrhoea, bacterial diarrhea and virus diarrhea is made a general survey of,
On the one hand its incidence of disease highest, occupy all diarrhoea factors the overwhelming majority, simultaneously because have infectiousness because
This is also easy to produce popular morbidity, and its fatal rate higher is also the prominent embodiment of harmfulness in addition.
Treatment to bacterial diarrhea and virus diarrhea in the prior art is broadly divided into two aspects, is on the one hand
Symptomatic treatment after morbidity, the means recover slower, it is difficult to ensure to cure, and influence can be produced on producing meat ability；
On the other hand it is to reduce the incidence of disease by vaccinating, the method has preferable preventive effect, but such as preceding
It is literary described, due to causing the pathogenic microorganism classification of grice diarrhoea various, it is difficult to realized by vaccine complete pre-
It is anti-.So if a kind of medicine of wide spectrum can be developed, by pharmaceutical intervention, lifting immune system is to one
The defense reaction of epidemy pathogenic microorganism, will be expected to obtain more preferably, more easily therapeutic effect.
The content of the invention
It is contemplated that for the technological deficiency of prior art, there is provided a kind of gut flora based on Yolk antibody is adjusted
Section medicine, to solve the technical problem of grice diarrhoea medicine unsatisfactory curative effect in the prior art.
Another technical problem that the present invention is solved is to provide a kind of new grice diarrhoea medicine.
Another technical problem that the present invention is solved is difficult in the prior art by a kind of several differences of drug therapy
Grice diarrhoea caused by pathogenic microorganism.
To realize above technical purpose, the present invention uses following technical scheme：
A kind of gut flora regulating drug based on Yolk antibody, including Yolk antibody, probiotics, interferon,
Azithromycin.
Preferably, the Yolk antibody makes IgG antibody.
Preferably, the Yolk antibody is from by transmissible gastro-enteritis virus vaccine or Porcine epidemic diarrhea virus
Hen after vaccine or Porcine rotavirus vaccine are immune extracts what is obtained in producing egg.It is further on this basis
Preferably, the extraction is comprised the following steps：
1) transmissible gastro-enteritis virus vaccine or Porcine epidemic diarrhea virus vaccine or porcine rotavirus epidemic disease are utilized
Seedling immune hen, is immunized 3 times；
2) then cross 5~9d take height exempt from the yolk liquid of egg as raw material；
3) step 2 is taken) raw material, grind broken, then add yolk liquid 2.2~2.8 times of acetic acid of cumulative volume
Salt buffer, stirring, obtains dilution；
4) to step 3) caprylic acid of its cumulative volume 3~5% is added in the dilution, stirring is then filtered
Clarification, takes supernatant as Yolk antibody solution.
Following technology can further be performed preferred：Step 1) in 3 immune time intervals be 12~16d；
Step 3) described in acetate buffer temperature be 50~56 DEG C, pH be 4.8~5.2；Step 4) described in
Filtering, be using specification for 750B polypropylene fibre filter cloth realize；Step 3) in first filter and be ground again
Broken, the filtering can be realized using 60 mesh nylon mesh；Step 3) time of the stirring is
25~35min；Step 4) time of the stirring is 80~100min；Step 3) described in grinding broken be
Realized using colloid mill.
Preferably, the probiotics is the living bacterial liquid of Bacillus acidi lactici or Bifidobacterium or bacillus；It is basic herein
Above it is further preferred that the cell concentration of each strain is not less than 10 in the living bacterial liquid8CFU/ml。
Preferably, the diarrhoea is by transmissible gastro-enteritis virus or Porcine epidemic diarrhea virus or pig colyliform disease
What poison caused a disease.
Yolk antibody, probiotics, interferon, azithromycin be used in combination novelty of the present invention, Ke Yishi
Now to the prevention or treatment of grice diarrhoea, formulation can select oral agents or injection.When to prevent as purpose,
Yolk antibody oral liquid 1ml+ probiotics 1ml, gavage to just birth piggy, continuously gavage 2d；When with treatment
During for purpose, Yolk antibody oral liquid or the prebiotic fungus oral 1ml of parenteral solution 1ml+, diarrhoea is continuously treated by piglet
3~5 days, severe patient was continuously treated 7 days.
Medicine of the present invention by piglet apply IgG antibody can in immune response activating complement, neutralize it is various
Toxin, so as to play prevention or therapeutic effect to the pathogenic microorganism for causing diarrhoea.And administration of probiotics can be to stomach
Gut flora plays intervention effect, promotes the releveling of sick body gastrointestinal bacterial flora, so that auxiliary treatment.The present invention
Prominent technique effect is realized with the technology design of novelty, its is evident in efficacy and easily prepared, therefore has
Prominent promotion prospect.
Specific embodiment
Specific embodiment of the invention will be below described in detail.In order to avoid excessive unnecessary details,
Be will not be described in detail to belonging to known structure or function in the examples below.In addition to being defined, below
Technology used and scientific terminology have the phase being commonly understood by with those skilled in the art of the invention in embodiment
Same implication.
Embodiment 1
A kind of gut flora regulating drug based on Yolk antibody, including Yolk antibody, probiotics, interferon,
Azithromycin.
Its preparation method is as follows：
1) using transmissible gastro-enteritis virus vaccine, Porcine epidemic diarrhea virus vaccine, porcine rotavirus epidemic disease
Seedling immune hen, it is each immune 3 times；
2) then cross 5d take height exempt from the yolk liquid of egg as raw material；
3) step 2 is taken) raw material, grind broken, then add 2.2 times of acetate of yolk liquid cumulative volume to delay
Fliud flushing, stirring, obtains dilution；
4) to step 3) caprylic acid of its cumulative volume 3% is added in the dilution, stirring is then filtered clear
Clearly, supernatant as Yolk antibody solution is taken.
Wherein：Step 1) in 3 immune time intervals be 12d；Step 3) described in acetate salt buffer
The temperature of liquid is 50 DEG C, and pH is 4.8；Step 4) described in filtering, be using specification for 750B third
What synthetic fibre filter cloth was realized.
In above technical scheme, the probiotics is the living bacterial liquid of Bacillus acidi lactici, Bifidobacterium, bacillus,
The cell concentration of each strain is 10 in the living bacterial liquid8CFU/ml。
Embodiment 2
A kind of gut flora regulating drug based on Yolk antibody, including Yolk antibody, probiotics, interferon,
Azithromycin.
Its preparation method is as follows：
1) it is each immune 3 times using transmissible gastro-enteritis virus vaccine, Porcine rotavirus vaccine immune hen；
2) then cross 9d take height exempt from the yolk liquid of egg as raw material；
3) step 2 is taken) raw material, grind broken, then add 2.8 times of acetate of yolk liquid cumulative volume to delay
Fliud flushing, stirring, obtains dilution；
4) to step 3) caprylic acid of its cumulative volume 5% is added in the dilution, stirring is then filtered clear
Clearly, supernatant as Yolk antibody solution is taken.
Wherein：Step 1) in 3 immune time intervals be 16d；Step 3) described in acetate salt buffer
The temperature of liquid is 56 DEG C, and pH is 5.2；Step 4) described in filtering, be using specification for 750B third
What synthetic fibre filter cloth was realized；Step 3) in first filter and be ground again broken, the filtering is using 60 mesh nylon
What sieve was realized；Step 3) time of the stirring is 30min；Step 4) time of the stirring is 90min；
Step 3) described in grinding it is broken be using colloid mill realization.
In above technical scheme, the probiotics is the living bacterial liquid of Bacillus acidi lactici, Bifidobacterium, the living bacterial liquid
In each strain cell concentration be 2 × 108CFU/ml。
Embodiments of the invention have been described in detail above, but the content is only preferable implementation of the invention
Example, is not intended to limit the invention.All any modification, equivalents made in application range of the invention
With improve etc., should be included within the scope of the present invention.
Claims (10)
1. a kind of gut flora regulating drug based on Yolk antibody, it is characterised in that including Yolk antibody, benefit
Raw bacterium, interferon, azithromycin.
2. medicine according to claim 1, it is characterised in that the Yolk antibody is IgG antibody.
3. medicine according to claim 1, it is characterised in that the Yolk antibody is from by pig transmissible
Hen after marcy agent vaccine or Porcine epidemic diarrhea virus vaccine or Porcine rotavirus vaccine are immunized is produced
Extract what is obtained in egg.
4. medicine according to claim 3, it is characterised in that the extraction is comprised the following steps：
1) transmissible gastro-enteritis virus vaccine or Porcine epidemic diarrhea virus vaccine or porcine rotavirus epidemic disease are utilized
Seedling immune hen, is immunized 3 times；
2) then cross 5~9d take height exempt from the yolk liquid of egg as raw material；
3) step 2 is taken) raw material, grind broken, then add yolk liquid 2.2~2.8 times of acetic acid of cumulative volume
Salt buffer, stirring, obtains dilution；
4) to step 3) caprylic acid of its cumulative volume 3~5% is added in the dilution, stirring is then filtered
Clarification, takes supernatant as Yolk antibody solution.
5. medicine according to claim 4, it is characterised in that step 1) between 3 immune times
It is divided into 12~16d.
6. medicine according to claim 4, it is characterised in that step 3) described in acetate buffer
Temperature be 50~56 DEG C, pH be 4.8~5.2.
7. medicine according to claim 4, it is characterised in that step 4) described in filtering, be profit
With the polypropylene fibre filter cloth realization that specification is 750B.
8. medicine according to claim 1, it is characterised in that the probiotics is Bacillus acidi lactici or bifid
Bacillus or the living bacterial liquid of bacillus.
9. medicine according to claim 8, it is characterised in that the thalline of each strain is dense in the living bacterial liquid
Degree is not less than 108CFU/ml。
10. medicine according to claim 1, it is characterised in that the diarrhoea is by transmissible gastroenteritis of swine
What virus or Porcine epidemic diarrhea virus or porcine rotavirus were caused a disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510872579.5A CN106806892A (en) | 2015-12-02 | 2015-12-02 | A kind of gut flora regulating drug based on Yolk antibody |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510872579.5A CN106806892A (en) | 2015-12-02 | 2015-12-02 | A kind of gut flora regulating drug based on Yolk antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106806892A true CN106806892A (en) | 2017-06-09 |
Family
ID=59108512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510872579.5A Pending CN106806892A (en) | 2015-12-02 | 2015-12-02 | A kind of gut flora regulating drug based on Yolk antibody |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106806892A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108888762A (en) * | 2018-08-15 | 2018-11-27 | 福建傲农生物科技集团股份有限公司 | A kind of composition of the metabolite containing probiotics |
| CN113845588A (en) * | 2021-05-26 | 2021-12-28 | 西南民族大学 | Preparation method and application of yolk antibody for resisting porcine rotavirus |
-
2015
- 2015-12-02 CN CN201510872579.5A patent/CN106806892A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108888762A (en) * | 2018-08-15 | 2018-11-27 | 福建傲农生物科技集团股份有限公司 | A kind of composition of the metabolite containing probiotics |
| CN113845588A (en) * | 2021-05-26 | 2021-12-28 | 西南民族大学 | Preparation method and application of yolk antibody for resisting porcine rotavirus |
| CN113845588B (en) * | 2021-05-26 | 2023-06-09 | 西南民族大学 | Preparation method and application of yolk antibody for resisting porcine rotavirus |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Roy et al. | Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives | |
| Lange et al. | Effects of antibiotics on gut microbiota | |
| RU2731148C2 (en) | Composition for use in preventing or treating infections/inflammations in the gastrointestinal tract in infants or young children | |
| Im et al. | Recent advances in Saccharomyces boulardii research | |
| Hwang et al. | Role of recent therapeutic applications and the infection strategies of Shiga toxin-producing Escherichia coli | |
| WO2018071534A1 (en) | Compositions and methods for treating irritable bowel syndrome and related disorders | |
| Sim et al. | The ameliorative role of probiotics in 5-fluorouracil induced intestinal mucositis | |
| CN106806892A (en) | A kind of gut flora regulating drug based on Yolk antibody | |
| TW201609149A (en) | Composition for oral delivery of bioactive agents | |
| CN106729706A (en) | A kind of immune response regulation medicine based on IgG antibody | |
| CN105535580A (en) | A biological agent for improving human body intestinal floras and a preparing method thereof | |
| CN104352501B (en) | A kind of compound ceftiofur sodium injection | |
| US20180099011A1 (en) | Compositions and Methods for Treating Irritable Bowel Syndrome and Related Disorders | |
| CN107405389A (en) | Contain bactericidal composition of the ADK albumen as active component, or for preventing or treating the composition of septicemia | |
| EA022278B1 (en) | Pharmaceutical composition for the prophylaxis and treatment of infectious and non-infectious diarrhoea | |
| JP2005537236A (en) | Probiotic treatment | |
| KR20040033616A (en) | Pediococcus pentosaceus CBT-8 which produces antimicrobial materials for restraining Helicobacter pylori and Listeria monocytogenes, and Production method of antimicrobial materials from Pediococcus pentosaceus CBT-8, and Application process for functional foods and/or drugs using the strain and the antimicrobial materials | |
| CN115052609A (en) | A bacterial composition for treating cancer | |
| Nagata et al. | Successful eradication of Helicobacter pylori with a herbal medicine, goshuyuto (Wu Zhu Yu Tang), plus rabeprazole after failure of triplet therapy with vonoprazan: A report of three cases. | |
| Das et al. | Probiotics in the prevention and treatment of infections with Helicobacter pylori, Enterohemorrhagic Escherichia coli, and Rotavirus | |
| CN111565745B (en) | Ostrich antibody for bacterial infection | |
| CN103127509A (en) | Medicine composition and preparation method and purpose | |
| Çavdar et al. | Alternative therapeutic applications used in the treatment of ulcerative colitis: probiotics, prebiotics, synbiotics and fecal microbiota transplantation | |
| Sun et al. | Characterization and immunological evaluation of chitosan nanoparticles as adjuvants for bovine coronavirus N protein | |
| US11529375B2 (en) | Compositions and methods for treating diverticulitis and related disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170609 |